Jasper Therapeutics Inc (JSPR) Stock Analysis
Verdict: AVOID
Severe cash burn creates an urgent 4.5-month runway crisis for briquilimab, driving acute dilution risk despite pipeline optionality.
Investment score: 25/100
Analysis as of
Is Jasper Therapeutics Inc stock worth reviewing? The TradeMates thesis
The model evaluates Jasper Therapeutics (JSPR) as AVOID due to severe cash burn, imminent dilution risk within a estimated 4.5-month cash runway, and negative analyst revisions.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Jasper Therapeutics Inc opportunities and risks
What speaks for JSPR
- Lead candidate briquilimab targets validated pathways in CD117-driven mast cell diseases
What speaks against JSPR
- Imminent cash exhaustion requiring massive equity dilution by mid-2026
Frequently asked questions about Jasper Therapeutics Inc (JSPR)
Is JSPR stock a good investment?
The TradeMates model rates Jasper Therapeutics Inc as AVOID with an investment score of 25/100. The model evaluates Jasper Therapeutics (JSPR) as AVOID due to severe cash burn, imminent dilution risk within a estimated 4.5-month cash runway, and negative analyst revisions. This is algorithmic model output, not personal investment advice.
Is JSPR stock a buy?
The TradeMates model verdict for JSPR is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.